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Objective: To compare the frequency of low APGAR scores in babies born to normotensive patients with asymptomatic 
hyperuricemia with those without hyperuricemia. 
Materials and Methods: This cohort study was conducted at the department of gynaecology/obstetrics, Liaquat National 
Hospital Karachi from January 2015 to January 2016. The sample size was calculated by using openepic.com version 2, an 
open-source calculator. The sample size was calculated to be 165 in each group, which made a total of 330 patients. Non-
probability consecutive sampling was chosen as the sampling technique. All normotensive pregnant females with blood 
pressure of less than 130/90 between 18 to 40 years of age, with singleton pregnancy at 37 weeks and beyond were included 
in the study. Normotensive pregnant females with hyperuricemia were the exposed group while normotensive pregnant 
females with normal uric acid levels were the non-exposed group. The exclusion criteria included patients with multiple 
gestations, medical disorders like gout, chronic renal failure, APLS, Rheumatoid Arthritis, etc, on anti-hypertensives and 
smokers. Fetal outcomes were assessed in all patients after delivery and a comparison of outcomes was made between two 
groups.  
Results: The study was designed to compare the frequencies of low APGAR scores in babies born to normotensive patients 
with asymptomatic hyperuricemia to those without hyperuricemia. The main outcome in group A i.e. exposed group was 29 
babies with low APGAR score (<7) with 17.5% and in group B, which was non-exposed, 12 (7.57%) of babies had low APGAR 
score (<7). P-value came out to be 0.0010. The difference was statistically significant. 
Conclusion: It is concluded that there is a significant difference between the frequency of low APGAR scores in babies born to 
normotensive patients with hyperuricemia to those without hyperuricemia. 
Keywords: Hyperuricemia, uric acid, APGAR score. 






The continuous effort to optimize maternal and fetal 
health is of crucial importance in leading to extensive 
research in the field of obstetrics and gynecology. 
Maternal health during pregnancy is of utmost 
importance for an acceptable fetal outcome. It is a fact 
that the majority of maternal and perinatal morbidity 
and mortality is contributed by pre-eclampsia which 
complicates around 2 – 8% of pregnancies.1 Uric acid 
produced as a final byproduct of purine degradation 
in the liver by endogenous and exogenous precursor 
proteins is mainly excreted via kidneys (65%) and 
intestines (35%). At normal physiologic concentrations, 
excellent anti-oxidant activity is exhibited by uric acid, 
but in the case when uric acid exceeds normal levels in 
plasma, oxidative damage is triggered. A chronic rise 
in the uric acid level is a significant risk factor for 
inflammation and dysfunction of endothelial cells.2,3 
The threshold values of 6 mg/dl (530 u /L) and 
5.6mg/dl at 38 weeks of pregnancy have been 
extensively reported in the literature, whereas, a mean 
uric acid level of 363 umol /L or more is reported4,5 to 
be associated with unfavourable outcomes during 
pregnancy6. Recent evidence has reported that 
hyperuricemia in the fetus itself is associated with 
infant respiratory distress syndrome.7 A research 
estimated that 20% of the general population suffers 
from asymptomatic hyperuricemia.8 Though not 
proven, the circulating uric acid may be directly 
responsible for the adverse fetal outcome rather than 
these effects being observed due to pre-eclampsia and 
other diseases indirectly.9 
It has been shown that uric acid freely crosses the 
placenta. It has also been demonstrated that levels of 
uric acid vary according to gestational age.10 Serum 
uric acid estimation has been demonstrated as a 
marker for preeclampsia in hypertensive 
pregnancies.11 It is however not routinely 
recommended for use in normotensive pregnant 
patients. A very recent study demonstrated that 
asymptomatic hyperuricemia in normotensive patients 
carried a poor fetal outcome as they observed that 
17.4% of neonates born to such females had 
significantly low APGAR scores while only 7.3% of 
neonates born to females with normal serum uric acid 
had low APGAR score.9 This is the only study 
undertaken previously to the best of our knowledge, 
but the issue highlighted is a grave one. With a 20% 
prevalence of asymptomatic hyperuricemia in 
population8, it may be the silent morbidity of many 
babies born with low APGAR score to mothers with no 
obvious risk factors. 
No study has been done in Pakistan till now; therefore 
this study aimed to assess the findings of this research 
in Pakistan, both for investigation of this hypothesis 
and to provide a local context in the matter. 
 
Materials and Methods 
 
The Cohort study was conducted at the obstetrics and 
gynecology department of Liaquat National Hospital 
Karachi over a period of one year i.e., from 1st January 
2015 to January 2016 after taking permission from the 
ethical committee of the hospital. The sample size was 
calculated by using openepi.com version 2, open-
source calculation taking the prevalence of low 
APGAR score in babies of mothers with hyperuricemia 
to be 17.4% and 7.3% to those babies born to mothers 
without hyperuricemia. The sample size was 
calculated to be 165 in each group, which made a total 
of 330 patients. Non-probability consecutive sampling 
was chosen as sampling technique Serum uric acid 
was considered raised in pregnancy based on 
gestational age i.e., at 37 weeks and 1 day and over 
more than 5.58 mg/dl. Blood pressure of less than 
130/90 mmHg was considered normal. APGAR score 
was calculated at one and five minutes according to 
the table given below. 
 
Signs  0 1 2 
HR (bpm) Not 
present 
< 100 >100 




Good crying  







in nostril  
No 
response  
Grimace Cough or 
sneeze  





*HR=Heart Rate, RR=Respiratory Rate, MT=Muscle Tone 
A score of < 7 was considered as a low APGAR score 
in this study. 
All normotensive pregnant females between the ages 
of 18 and 40 years with singleton pregnancies 
confirmed by ultrasound at 37 weeks of gestation and 
beyond confirmed from LMP or in case of not sure of 
dates from first dating scan were included in the 
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study. Pregnant females with hyperuricemia were the 
exposed group (A) and pregnant females with normal 
uric acid levels were the non-exposed group (B). 
The exclusion criteria consisted of twins and higher-
order gestation confirmed by ultrasound, patients on 
antihypertensive drugs, or having blood pressure of 
more than 130/90mmHg with a history of gout and 
chronic renal disease. Patients who smoked or have a 
history of substance abuse and those with 
autoimmune illness were excluded from enrollment in 
the study. 
After taking informed written consent, the blood 
sample was drawn and a sample was sent for serum 
uric acid levels to the laboratory. Upon receiving the 
results, patients were placed accordingly in either the 
asymptomatic hyperuricemia group (A) or the normal 
serum uric acid group (B). Once delivered, the APGAR 
score of the baby was calculated at one and five 
minutes. A proforma was used to record the patient’s 
demographic profile i.e., age, gestational age, parity, 
group of the patients, body mass index, mode of 
delivery, the value of APGAR score at one minute and 
five minutes, and an outcome that is APGAR score at 5 
minutes, serum uric acid levels. Data were analyzed 
by using SPSS version 13.0. Mean values and standard 
deviations were computed for numerical variables like 
age, parity serum uric acid levels and APGAR score. 
The outcome was a low APGAR score that was 
labelled as positive when the score was < 7. The 
frequency of low APGAR score was compared 
between the two groups and a chi-square test was 
applied and a P-value of <0.05 was considered 




This study compared the frequencies of low APGAR 
score in babies born to normotensive patients with 
asymptomatic hyperuricemia to those without 
hyperuricemia.  
A total of 330 patients were enrolled in the study. The 
age-wise distribution in 18-25 years in group A was 49 
(29.69%) and group B was 46 (27.87%). In the age 
group, 26-30 years 27 patients (16.36%) belonged to 
group A and 42 (25.45%) patients belonged to group B. 
in the age group of 31-35 years, 58 (35.15%) were in 
group B. in 36-40 years age group, 31 (18.78%) patients 
belonged to group A and 36 (21.81%) patients 
belonged to group B. Mean and SD for age, parity, 
BMI, serum uric acid and APGAR score is given in 
tables below. 
152 patients (92.12%) had a normal vaginal delivery 
and 13(7.87%) had a caesarean section in group A, 
whereas in group B 159(96.36%) patients had a normal 
vaginal delivery and 06(3.63%) had a caesarean 
section. The main outcomes i.e., babies born with low 
APGAR score in group A were 29(17.5%) and in group 
B it was 12(7.57%) with a P-value of 0.0010. 
Stratification of main outcomes with age, gestational 
age, parity, and mode of delivery is presented in 
Tables: 4,5,6, and 7 respectively. 
 
Table 1: Age Distribution n = 330 
Age Group Group A Group B 
18-25 years  49 (29.69%) 46 (27.37%) 
26-30 years 27 (16.36%) 42 (25.45%) 
31-35 years 58 (35.15%) 41 (24.84%) 
36-40 years 31 (18.78%) 36 (21-81%) 
Mean and SD for age 31- + 5.7 30 + 6.41 
 
Table 2: Mean and SD for Demographic Variables n 
= 330 
Mean and SD Group A Group B 
Age 31 + 5.7 30 + 6.41 
Parity  2 +0.81 2 + 0.97 
BMI 26 + 1.17 26 + 1.67 
Serum uric acid 6.7 + 0.316 5.2 + 0.55 
APGAR score at 
01 minute 
9 + 1.34 9 + 0.99 
APGAR score at 
05 minute 
9 + 1.34 9 + 0.99 










Table 3: Frequencies and Percentages for Mode of Delivery n=330 
Mode of Delivery  
 
Normal Vaginal Delivery  
Groups A Group B 
Frequencies Percentages Frequencies Percentages 
152 92.19% 159 96.3% 
Caesarean Section 13 7.87% 06 3.6% 
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Table 4: Comparison of Frequencies and Percentages for Low APGAR Score (Main Outcome) n=330 
Low APGAR score the main outcome 
 
Yes 
Groups A Group B 
Frequencies Percentages Frequencies Percentages 
29 17.57% 12 7.57% 
No 136 82.42% 153 42.72% 
P-Value = 0.0010 
Table 5: Stratification of Mean Outcome with 














37 weeks Yes 15 04 0.005 
No 62 72 
>37 weeks Yes 14 08 0.189 
0.189 No 74 78 
 
Table 6: Stratification of Mean Outcome with mode 

















Yes 16 06 0.009 
No 136 153 
Caesarean 
section  
Yes 13 06  




Adverse fetal outcomes are significantly associated 
with hyperuricemia in pregnancy.  Fetal growth is 
suppressed by a higher uric acid concentration during 
pre-eclampsia by directly inhibiting amino acid 
transfer in the placenta.12 It is known that the 
production of pro-inflammatory substances and 
vasoconstrictors is stimulated by uric acid, which 
lowers nitric oxide production and tends to increase 
the production of thromboxane in vascular smooth 
muscle cells.13 As result hyperuricemia is associated 
with endothelial dysfunction and raised serum uric 
acid levels which then precede hypertension. In 
normotensive pregnant females increased serum uric 
acid in midgestation is associated with insulin 
resistance and lower birth weights.14 
The prevalence of hyperuricemia is reported to be 
increasing worldwide in recent years. An increase in 
serum uric acid levels and increased consumption of 
sugar-sweetened beverages, food rich in purines, and 
alcohol contribute to a higher prevalence of obesity.15,16 
Our study is comparable to a study done by Amini E 
et al9, where it was observed that 17.4% of neonates 
born to females with asymptomatic, normotensive 
hyperuricemia had low APGAR score while only 7.3% 
of neonates born to females with normal uric acid had 
APGAR score. This difference was statistically 
significant. In another study by Chang FM et al10, 
maternal and neonatal uric acid levels were measured 
simultaneously in pregnant women with and without 
gestational hypertension. There was a high correlation 
and minimal concentration difference between 
maternal and neonatal uric acid in either normal or 
hypertensive women suggesting free transfer of uric 
acid through the placenta in both directions. 
Moreover, not only maternal and neonatal uric acid 
levels were significantly different among normal and 
hypertensive females but showed higher levels of 
serum uric acid in accordance with the severity of 
preeclampsia.  
Both maternal and neonatal uric acid had a negative 
correlation with birth weight, one minute APGAR 
score, and five minute APGAR score. It is implied that 
uric acid levels at parturition might provide a 
reference index for fetal outcomes in pregnancy with 
gestational hypertension. 
Elevated serum uric acid in pregnant women is 
associated with small for gestational age due to 
decreased amino acids uptake by the placenta.17 
Among normotensive pregnant females, 
hyperuricemia acts as a risk factor for adverse 
pregnancy outcomes and subsequent development of 
neonatal hypoglycemia and IVH. 
In one study, neonatal hyperuricemia was linked to 
infant respiratory distress syndrome and asphyxia.18 
Maternal factors that lead to increased maternal serum 
uric acid levels are younger age, primigravidity, 
increased weight gain, and deranged renal function 
during pregnancy. These associations have been 
pointed out by other studies.19 
Results of this study suggesting a significant 
association between umbilical, maternal, and neonate 
uric acid levels are supported by literature 
demonstrating the free transfer of uric acid through 
placenta tissue. It is suggested that the etiology of poor 
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neonatal outcomes might be associated with raised 
maternal uric acid levels. Neonatal hyperuricemia can 
only be a reflection of maternal hyperuricemia which 
triggers an oxidation effect leading to inflammation 




Very few studies have been done regarding this topic, 
so more research needs to be done. Taking this study 
as a reference point, further multicentered research 




There is a statistical difference between the frequency 
of low APGAR score in babies born to normotensive 
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